Alumis says envudeucitinib hits 54% PASI 100 at 48 weeks in ONWARD3 plaque psoriasis extension study
ALMS•Topline extension results from ONWARD3
Alumis reported topline long-term extension results for envudeucitinib in moderate-to-severe plaque psoriasis on Aug. 10, 2026.
- Patients on continued treatment showed rising rates of complete skin clearance over 48 weeks, supporting durable disease control with an oral therapy.
- Safety and tolerability stayed consistent with earlier Phase 3 trials, with no new safety signals flagged in the extension study.
- The group plans to present additional ONWARD program data at upcoming medical meetings.
- An FDA New Drug Application filing is targeted for 4Q 2026.
